Figure 5(B) demonstrates that the HER2-LsbMDDs significantly enhanced the in vivo anticancer activity, as shown by the higher growth inhibition rate in the HER2-overexpressing tumor cells. The gene discussed is ERBB2; the disease is neoplasm.